Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC9684 EL102 Featured EL-102 is a dual-inhibitor of apoptosis and angiogenesis, and exerts its action though the inhibition of Hif1 alpha induced hypoxic signalling pathways and induction of the Caspase 3/7 apoptotic cascade.
DC10182 Elacestrant (dihydrochloride) Featured Elacestrant dihydrochloride (RAD1901 dihydrochloride) is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively.
DC10208 Elacestrant S enantiomer Elacestrant S enantiomer is an low activity enantiomer of elacestrant. Elacestrant (RAD1901) is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively.
DC8301 Elacridar Featured Elacridar is an orally selectly potent P-glycoprotein (P-gp/ABCG1) inhibitor.
DC11192 Elacytarabine Elacytarabine (CP-4055, CP4055) is a fatty acid derivative of cytarabine with potential antineoplastic activity.
DC10727 Elafibranor(GFT505) Featured Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α (PPAR-α) and peroxisome proliferator-activated receptor-δ (PPAR-δ) with EC50 values of 45 and 175 nM, respectively.
DC10032 Elagolix sodium Featured Elagolix is a Gonadotropin-Releasing Hormone (GnRH) Antagonist.
DC7407 Elagolix Featured Elagolix is a Gonadotropin-Releasing Hormone (GnRH) Antagonist.
DC22394 Elaiophylin Elaiophylin (Gopalamicin.
DC22182 Elatol Elatol (NSC 341593) is a specific inhibitor of ATP hydrolysis by eIF4A1 in vitro with broad activity against multiple tumor types.
DC9295 Elbasvir(MK-8742) Featured Elbasvir (MK-8742) is a small-molecule inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.
DCAPI1410 Eldecalcitol Featured Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is an analog of 1,25-dihydroxyvitamin D3 that improves bone mineral density. Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is more efficaci
DC9980 Eleclazine(GS-6615) Featured Eleclazine(GS-6615) is a selective late sodium current inhibitor.
DC11551 Elenbecestat Featured Elenbecestat (E2609) is a novel potent, oral BACE1 inhibitor for treatment of Alzheimer's disease..
DC3156 Elesclomol (STA-4783) Featured Elesclomol (STA-4783) is a novel potent oxidative stress inducer that illicits pro-apoptosis events among tumor cells..
DC21774 Eletriptan Eletriptan (UK 116044) is a potent, selective, and orally active 5-HT1B/1D receptor agonist.
DC8323 Eletriptan HBr Featured Eletriptan HBr is an orally active, selective 5-HT1B/1D receptor agonist.
DC9291 Eliglustat hemitartrate (Genz-112638) Featured Eliglustat is a specific and potent inhibitor of glucosylceramide synthase.
DC9290 Eliglustat(Genz-99067) Featured Eliglustat is a specific and potent inhibitor of glucosylceramide synthase.
DC7772 Elinogrel Elinogrel is a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events.
DC8268 Eliprodil Featured Eliprodil is a non-competitive NMDA receptor antagonist that acts at the polyamine modulatory site.
DC10410 Ellipticine hydrochloride Featured Ellipticine hydrochloride is a potent antineoplastic agent; inhibits DNA topoisomerase II activities.
DC8325 Ellipticine Featured Ellipticine is a DNA intercalating agent and a DNA topoisomerase II inhibitor.
DC7786 ELN 441958 Featured ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM. ELN-441958 is highly selective for B1 over B2 receptors, and >500/ 2000-fold selective for the B1 over μ/δ-opioid receptor.IC50 value: 0.26 nM (Ki)Target: B1 Receptorin vitro: ELN-441958 is a novel small molecule bradykinin B1 receptor antagonist, based on the inhibition of agonist-induced increases in intracellular calcium in native and recombinant cells. ELN-441958 does not inhibit the activation of the human bradykinin B2 receptor at concentrations up to 10 μM, showing that it is highly selective for B1 over B2 receptors. ELN-441958 also displays good selectivity for B1 over other receptors examined in a broad screening panel. It is >500-fold and >2000-fold selective for the B1 receptor over the human μ- and δ-opioid receptor, the most potent off-target activity identified. In IMR-90 cells expressing the native human B1 receptor, ELN-441958 produced a concentration-dependent antagonism of the DAKD-induced calcium mobilization with a KB of 0.12 nM. [1]in vivo: ELN-441958 is essentially completely absorbed and produces high plasma levels after oral administration in rhesus monkeys.ELN-441958 has a moderate clearance and volume of distribution in both species following i.v. administration, consistent with the high metabolic stability in rat, rhesus, and human microsomes. ELN-441958 has high oral exposure and moderate plasma half-lives in rats and rhesus monkeys. The oral availability of ELN441958 in rats was 57%. ELN-441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED50 3 mg/kg s.c. [1]
DC10740 ELN484228 Featured ELN484228 is a blocker of α-synuclein which is a key protein in Parkinson’s disease.
DC7779 ELND0006 ELND006 is a novel gamma secretase inhibitor previously under investigation for the oral treatment of Alzheimer's disease.
DCAPI1504 Elocalcitol Elocalcitol
DC20268 ELQ300 Featured ELQ300 is a novel inhibitor of the mitochondrial cytochrome bc1 complex (complex III in the electron transport chain).
DCAPI1196 Eltrombopag (SB-497115-GR) Featured Eltrombopag (SB-497115-GR)
DC8369 Eltrombopag olamine Featured Eltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis.

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X